Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates

被引:34
作者
Cali, James J. [1 ]
Ma, Dongping [1 ]
Wood, Monika G. [1 ]
Meisenheimer, Poncho L. [2 ]
Klaubert, Dieter H. [3 ]
机构
[1] Promega Corp, Madison, WI 53711 USA
[2] Promega Biosci, Chem Res, San Luis Obispo, CA 93401 USA
[3] Promega Biosci, Adv Technol, Chem, San Luis Obispo, CA 93401 USA
关键词
ADME; bioluminescence; CYP induction; CYP inhibition; cytochrome P450; drug interaction; drug metabolism; high throughput; luciferase; luciferin; PRIMARY HUMAN HEPATOCYTES; DRUG-METABOLISM; IN-VITRO; ENZYME-ACTIVITIES; SCREENING ASSAYS; INDUCTION; EXPRESSION; PREDICTION; RAT; INVOLVEMENT;
D O I
10.1517/17425255.2012.695345
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: The cytochrome P450s (CYPs) are central to ADME studies because of their central role in drug metabolism. Proper CYP assay design and a correct understanding of CYP assay selectivity are critical for generating and interpreting biologically relevant data during drug development. Bioluminescent CYP assays use luminogenic probe substrates that have the unique property of producing photons in a second reaction with luciferase. Areas covered: This article presents the general design principles for in vitro CYP assays. Specifically, the article focuses on the bioluminescent approach that couples CYP activity with photon production. Expert opinion: Highly selective luminogenic substrates for CYP1A1, CYP1A2, CYP2C9, CYP3A4, CYP3A7, CYP4A and CYP4F have been developed with utility for interrogating the roles of these enzymes in biochemical and cell-based formats. These selective substrates are part of a larger collection of probes that deliver CYP inhibition and induction data that predict in vivo drug interactions. Furthermore, they support highly sensitive, rapid and scalable assays for cell-based and cell-free biochemical applications, which offer an alternative and often enabling option over conventional assay strategies.
引用
收藏
页码:1115 / 1130
页数:16
相关论文
共 71 条
  • [1] [Anonymous], 2012, GUID IND DRUG INT ST
  • [2] AOYAMA T, 1990, J LIPID RES, V31, P1477
  • [3] Site-directed mutagenesis of histidine 245 in firefly luciferase: A proposed model of the active site
    Branchini, BR
    Magyar, RA
    Murtiashaw, MH
    Anderson, SM
    Zimmer, M
    [J]. BIOCHEMISTRY, 1998, 37 (44) : 15311 - 15319
  • [4] NAPHTHYLLUCIFERIN AND QUINOLYLLUCIFERIN - GREEN AND RED-LIGHT EMITTING FIREFLY LUCIFERIN ANALOGS
    BRANCHINI, BR
    HAYWARD, MM
    BAMFORD, S
    BRENNAN, PM
    LAJINESS, EJ
    [J]. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1989, 49 (05) : 689 - 695
  • [5] Brosen K, 1993, BIOCH PHARM, P1211
  • [6] Cali J. J., 2006, CELL NOTES, V14, P20
  • [7] Cali JJ, 2008, EXPERT OPIN DRUG MET, V4, P103, DOI [10.1517/17425255.4.1.103, 10.1517/17425255.4.1.103 ]
  • [8] Luminogenic cytochrome P450 assays
    Cali, James J.
    Ma, Dongping
    Sobol, Mary
    Simpson, Daniel J.
    Frackman, Susan
    Good, Troy I.
    Daily, William J.
    Liu, David
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (04) : 629 - 645
  • [9] Cali JJ, RAPID CELL BASED BIO
  • [10] Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor
    Chen, YP
    Ferguson, SS
    Negishi, M
    Goldstein, JA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) : 495 - 501